Endocrine Therapy with Selective Estrogen Receptor Modulators (SERMs) and Aromatase Inhibitors in the Prevention and Adjuvant Therapy Settings.
作者： Shelly S. Lo , Kathleen I. Pritchard , Patricia Robinson , Kathy S. Albain
DOI: 10.1007/978-0-387-09463-2_7
关键词:
摘要:
springer.com
sci-hub.st 参考文章(77)
, Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. Journal of the National Cancer Institute. ,vol. 95, pp. 1833- 1846 ,(2003) , 10.1093/JNCI/DJG119
, Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses Cancer. ,vol. 98, pp. 1802- 1810 ,(2003) , 10.1002/CNCR.11745
Early Breast Cancer Trialist's Collaborative Group, Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. The Lancet. ,(1992) , 10.1016/0140-6736(92)90997-H
Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials The Lancet. ,vol. 369, pp. 1711- 1723 ,(2007) , 10.1016/S0140-6736(07)60778-8
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer The New England Journal of Medicine. ,vol. 353, pp. 2747- 2757 ,(2005) , 10.1056/NEJMOA052258
First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. The Lancet. ,vol. 360, pp. 817- 824 ,(2002) , 10.1016/S0140-6736(02)09962-2
J N Ingle, J E Krook, S J Green, T P Kubista, L K Everson, D L Ahmann, M N Chang, H F Bisel, H E Windschitl, D I Twito, Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer Journal of Clinical Oncology. ,vol. 4, pp. 178- 185 ,(1986) , 10.1200/JCO.1986.4.2.178
H B Muss, L D Case, J N Atkins, J D Bearden, M R Cooper, J M Cruz, D V Jackson, M A O'Rourke, M D Pavy, B L Powell, Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study. Journal of Clinical Oncology. ,vol. 12, pp. 1630- 1638 ,(1994) , 10.1200/JCO.1994.12.8.1630
T Saphner, D C Tormey, R Gray, Annual hazard rates of recurrence for breast cancer after primary therapy. Journal of Clinical Oncology. ,vol. 14, pp. 2738- 2746 ,(1996) , 10.1200/JCO.1996.14.10.2738